Safe molecular design that allows RI to be rapidly excreted into the urine by providing a tubule-specific enzyme cleavage sequence between the RI chelating site and the antibody
Peptide linker enhances the interaction between VH-VL within scFv molecules, which suppresses intermolecular association.
A novel therapeutic approach for systemic anti-tumor immunity utilizing apolipoproteins
Targeting soluble CD155, an immune escape mechanism of tumor cells, activates cancer immunity through DNAM-1-mediated activation signals on T cells
TribsMab CLC, a novel bispecific antibody format solves a manufacturing challenge
Molecular targeted drugs targeting the NIK associated with the differentiation factor from hepatocytes to cholangiocarcinoma
Prediction of the efficacy of cancer immunotherapy using the tumor-targeting activity of T cells in peripheral blood.
Biomarkers for prediction and diagnosis of interstitial pneumonia, a side effect of cancer treatment with immune checkpoint inhibitors
Original method and hepatocyte reproduced hepatobiliary function
CHRNB2, a novel target for gastric cancer, potentially other tumors
(Update): Anti-CKAP4 Monoclonal Antibody Obtained
Cell Surface Antigen CD48 as A Novel Molecular Target for Antibody Therapy in Multiple Myeloma
Investment / Co-development Opportunity for Start-up Company